BACKGROUND/AIM: Whether anesthesia can affect oncological outcomes in urothelial carcinoma of the upper urinary tract undergoing radical nephroureterectomy (RNU) is not clear. PATIENTS AND METHODS: One-hundred an ninety-seven patients who underwent RNU were retrospectively recruited and divided into total intravenous (TIVA, n=90) and volatile inhalation anesthesia (VIA, n=107) groups. A 1:1 propensity score-matching method was employed to minimize selection bias (n=70 each). Cancer-specific (CSS), overall (OS) and metastasis-free (MFS) survival were compared between groups before and after matching. RESULTS: For all survival endpoints, no significant differences were observed between the two study groups, both before (hazard ratio for TIVA: CSS: 0.70, OS: 0.75, MFS: 0.78) and after (hazard ratios for TIV: CSS: 1.21, OS: 0.82, MFS: 0.84) matching. CONCLUSION: With no survival difference observed according to anesthetic technique for RNU, the choice should be based on factors such as accessibility, prevention of side-effects, or costs.
BACKGROUND/AIM: Whether anesthesia can affect oncological outcomes in urothelial carcinoma of the upper urinary tract undergoing radical nephroureterectomy (RNU) is not clear. PATIENTS AND METHODS: One-hundred an ninety-seven patients who underwent RNU were retrospectively recruited and divided into total intravenous (TIVA, n=90) and volatile inhalation anesthesia (VIA, n=107) groups. A 1:1 propensity score-matching method was employed to minimize selection bias (n=70 each). Cancer-specific (CSS), overall (OS) and metastasis-free (MFS) survival were compared between groups before and after matching. RESULTS: For all survival endpoints, no significant differences were observed between the two study groups, both before (hazard ratio for TIVA: CSS: 0.70, OS: 0.75, MFS: 0.78) and after (hazard ratios for TIV: CSS: 1.21, OS: 0.82, MFS: 0.84) matching. CONCLUSION: With no survival difference observed according to anesthetic technique for RNU, the choice should be based on factors such as accessibility, prevention of side-effects, or costs.
Authors: Jennifer A Locke; Reza Hamidizadeh; Wassim Kassouf; Ricardo A Rendon; David Bell; Jonathan Izawa; Joseph Chin; Anil Kapoor; Bobby Shayegen; Jean-Baptiste Lattouf; Fred Saad; Louis Lacombe; Yves Fradet; Adrien S Fairey; Niels-Eric Jacobson; Darrel E Drachenberg; Ilias Cagiannos; Alan I So; Peter C Black Journal: Can Urol Assoc J Date: 2018-04-12 Impact factor: 1.862
Authors: Hans von der Maase; Lisa Sengelov; James T Roberts; Sergio Ricci; Luigi Dogliotti; T Oliver; Malcolm J Moore; Annamaria Zimmermann; Michael Arning Journal: J Clin Oncol Date: 2005-07-20 Impact factor: 44.544
Authors: Mats Enlund; Anders Berglund; Kalle Andreasson; Catharina Cicek; Anna Enlund; Leif Bergkvist Journal: Ups J Med Sci Date: 2014-05-26 Impact factor: 2.384